Cabozantinib and Nivolumab for older adults with kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial is testing a combination of two drugs, cabozantinib and nivolumab, in people aged 70 or older who have advanced kidney cancer that hasn't been treated yet. The goal is to see if this combination works well and is safe for older patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years old or older.
- You have advanced or metastatic kidney cancer that has not been treated before.
- You are able to take care of yourself (performance status 0 to 2).
- You do not have untreated brain tumors or an active autoimmune disease needing strong immune-suppressing drugs.
- You have not had a serious heart or blood clot problem in the last 3 months.
- You agree to use effective contraception if you are sexually active and male.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the drug cabozantinib in people with kidney cancer who are also on dialysis. It aims to see if the drug is safe and works for this group.
This study tests whether adding a drug called cabozantinib to standard nivolumab treatment helps fight kidney cancer that has spread to bone. It aims to understand how the bone environment changes during treatment.
This Phase 2 study tests a different dosing schedule of cabozantinib (a cancer medicine) for metastatic kidney cancer and certain neuroendocrine tumors. It aims to see if the timing and schedule can work well for people with advanced disease.
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
This trial tests a combination of two drugs (tivozanib and nivolumab) for people with advanced kidney cancer that is not clear cell type. It aims to see if this drug pair can shrink or slow the cancer.
This trial tests a new drug (casdatifan) combined with cabozantinib for advanced clear cell kidney cancer, comparing it to cabozantinib alone. It's for people who haven't taken these specific medicines before and are still in fairly good health.
Hear when a new Renal Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.